NuVasive will pay approximately $4.5 million for the company, which NuVasive has been involved with since 2010 as a manufacturing partner. Company executives said the deal will reduce the time for NuVasive device development; all 65 ANC employees will be retained.
More Articles on Supply Chain:
DePuy Receives FDA Supplemental Pre-Market Approval for Hip Devices
Smith & Nephew Revenue Down 4 percent in Q1, $300M Share Buyback Announced
Study: Limiting Device Company, Provider Relationships Could Hurt Innovation
